Readings

WEEK # TOPICS READINGS
1

Introduction

See the Lecture Summary

No Readings
2

Of tumor suppressors and oncogenes

See the Lecture Summary

Schwab, M., J. Ellison, et al. "Enhanced Expression of the Human Gene N–myc Consequent to Amplification of DNA may Contribute to Malignant Progression of Neuroblastoma." Proceedings of the National Academy of Sciences 81, no. 15 (1984): 4940–44.

Baker, S. J., S. Markowitz, et al. "Suppression of Human Colorectal Carcinoma Cell Growth by Wild–type p53." Science 249, no. 4971 (1990): 912–15.

3

Cancer stem cells and minimal residual disease

See the Lecture Summary

Lapidot, T., C. Sirard, et al. "A Cell Initiating Human Acute Myeloid Leukaemia after Transplantation into SCID Mice." Nature 367, no. 6464 (1994): 645–48.

Gerber, J. M., B. D. Smith, et al. "A Clinically Relevant Population of Leukemic CD34+CD38 Cells in Acute Myeloid Leukemia." Blood 119, no. 15 (2012): 3571–77.

4

Can we model human cancers in mice?

See the Lecture Summary

Harris, A. W., C. A. Pinkert, et al. "The E Mu–myc Transgenic Mouse. A Model for High–incidence Spontaneous Lymphoma and Leukemia of Early B Cells." The Journal of Experimental Medicine 167, no. 2 (1988): 353–71.

Ishikawa, F., S. Yoshida, et al. "Chemotherapy–resistant Human AML Stem Cells Home to and Engraft within the Bone–marrow Endosteal Region." Nature Biotechnology 25, no. 11 (2007): 1315–21.

5

Making a better Mouse Man—Recent developments in humanized mouse technologies

See the Lecture Summary

Shultz, Leonard D., Yoriko Saito, et al. "Generation of Functional Human T–cell Subsets with HLA–restricted Immune Responses in HLA Class I Expressing NOD/SCID/IL2rγnull Humanized Mice." Proceedings of the National Academy of Sciences 107, no. 29 (2010): 13022–27.

Lan, P., N. Tonomura, et al. "Reconstitution of a Functional Human Immune System in Immunodeficient Mice through Combined Human Fetal Thymus / Liver and CD34+ Cell Transplantation." Blood 108, no. 2 (2006): 487–92.

6

Sophisticated models of de novo human tumors in humanized mice

See the Lecture Summary

Moriya, K., M. Suzuki, et al. "Development of a Multi–step Leukemogenesis Model of MLL–rearranged Leukemia using Humanized Mice." PLoS One 7, no. 6 (2012): e37892.

Washburn, M. L., M. T. Bility, et al. "A Humanized Mouse Model to Study Hepatitis C Virus Infection, Immune Response, and Liver Disease." Gastroenterology 140, no. 4 (2011): 1334–44.

7

Visit to Chen Research Lab

See the Lecture Summary

No Readings
8

The immune system and cancer—Cancer Immunoediting hypothesis

See the Lecture Summary

Shankaran, V., H. Ikeda, et al. "IFN gamma and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity." Nature 410, no. 6832 (2001): 1107–11.

Muul, L. M., P. J., Spiess, et al. "Identification of Specific Cytolytic Immune Responses against Autologous Tumor in Humans Bearing Malignant Melanoma." Journal of Immunology 138, no. 3 (1987): 989–95.

9

T cell mediated immunotherapy

See the Lecture Summary

Attia, P., G. Q. Phan, et al. "Autoimmunity Correlates with Tumor Regression in Patients with Metastatic Melanoma Treated with Anti–cytotoxic T–Lymphocyte Antigen–4." Journal of Clnical Oncology 23, no. 25 (2005): 6043–53.

Vudattu, N. K., F. Waldron–Lynch, et al. "Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy." Journal of Immunology 193, no. 2 (2014): 587–96.

10

Improving combination chemotherapy and immune–based therapies based on lessons learned from humanized mice

See the Lecture Summary

Rambaldi, A., M. Lazzari, et al. "Monitoring of Minimal Residual Disease after CHOP and Rituximab in Previously Untreated Patients with Follicular Lymphoma." Blood 99, no. 3 (2002): 856–62.

Pallasch, C. P., I. Leskov, et al. "Sensitizing Protective Tumor Microenvironments to Antibody–mediated Therapy." Cell 156, no. 3 (2014): 590–602.

11

Personalized mice—Part 1: Mouse Avatars

See the Lecture Summary

Villarroel, M. C., N. V. Rajeshkumar, et al. "Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer." Molecular Cancer Therapeutics 10, no. 1 (2011): 3–8.

Garralda, E., K. Paz, et al. "Integrated Next–generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment." Clinical Cancer Research 20, no. 9 (2014): 2476–84.

12

Personalized mice—Part 2: Co–clinical trials

See the Lecture Summary

Chen, Z., K. Cheng, et al. "A Murine Lung Cancer Co–clinical Trial Identifies Genetic Modifiers of Therapeutic Response." Nature 483, no. 7391 (2012): 613–17.

Chen, Z., E. Akbay, et al. "Co–clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK–rearranged Non–small Cell Lung Cancer and Predict Strategies to Overcome Resistance." Clinical Cancer Research 20, no. 5 (2014): 1204–11.

13

Class presentation and course evaluation

See the Lecture Summary

No Readings